To evaluate the association between recent discontinuation of xanthine oxidase inhibitors (XOis) and the risk of acute cardiovascular events, specifically acute myocardial infarction and ischemic stroke, in a real-world outpatient population.
Key Findings:
Recent discontinuation of XOis was associated with an increased risk of acute cardiovascular events, with a notable increase in the incidence of acute myocardial infarction and ischemic stroke.
Interpretation:
The findings suggest that discontinuation of xanthine oxidase inhibitors may lead to heightened cardiovascular risk, supporting the need for careful management of gout patients on these medications, particularly in monitoring cardiovascular health.
Limitations:
The study is observational and may be subject to confounding factors.
Data was derived from claims databases, which may not capture all relevant clinical information, potentially introducing biases.
Conclusion:
Discontinuation of xanthine oxidase inhibitors is associated with an increased risk of acute cardiovascular events, highlighting the importance of continued therapy and monitoring in at-risk populations.
Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
